A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : CR / castration-resistant

[Related PubMed/MEDLINE]
Total Number of Papers: 61
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   CR  (>> Co-occurring Abbreviation)
Long Form:   castration-resistant
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 Targeting the Kynurenine Pathway for the Treatment of Cisplatin-Resistant Lung Cancer. IDO1, KYN, ROS, Trp
2019 Asparagine Synthetase and Filamin A Have Different Roles in Ovarian Cancer. ASNS, CS, FLNA, HGSC, LGSC
2019 Enabling precision medicine by unravelling disease pathophysiology: quantifying signal transduction pathway activity across cell and tissue types. PCa
2019 ErbB-2 signaling in advanced prostate cancer progression and potential therapy PCa
2019 Factors related to early castration resistance in metastatic prostate cancer. Results from the National Prostate Cancer Registry in Spain. PC
2019 Long noncoding RNA OIP5-AS1 causes cisplatin resistance in osteosarcoma through inducing the LPAATbeta/PI3K/AKT/mTOR signaling pathway by sponging the miR-340-5p. lncRNAs, MRP1, P-gp
2019 miR-146b Reverses epithelial-mesenchymal transition via targeting PTP1B in cisplatin-resistance human lung adenocarcinoma cells. EMT, PTP1B
2019 p66Shc protein through a redox mechanism enhances the progression of prostate cancer cells towards castration-resistance. AI, AS, NAC, PCa
2019 Riluzole induces AR degradation via endoplasmic reticulum stress pathway in androgen-dependent and castration-resistant prostate cancer cells. AD, AR, AR-V7, ERS, PCa
10  2019 Sema4C mediates EMT inducing chemotherapeutic resistance of miR-31-3p in cervical cancer cells. ---
11  2019 The Extract of Cordyceps Militaris Inhibited the Proliferation of Cisplatin-Resistant A549 Lung Cancer Cells by Downregulation of H-Ras. CME
12  2018 Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer. ADT, AR, ARV-PBS, ChIP-seq, CRPC
13  2018 BCL9 promotes epithelial mesenchymal transition and invasion in cisplatin resistant NSCLC cells via beta-catenin pathway. BCL9, EMT, NSCLC
14  2018 Current status of theranostics in prostate cancer. mp, PC, PRLT, PSA, PSMA
15  2018 Delineation of human prostate cancer evolution identifies chromothripsis as a polyclonal event and FKBP4 as a potential driver of castration resistance. HN, PC
16  2018 p66Shc regulates migration of castration-resistant prostate cancer cells. PCa, ROS
17  2018 Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer. ARB, BIC, ENZ, PC, PSMA, RLT
18  2018 Single-Cell Analysis Identifies LY6D as a Marker Linking Castration-Resistant Prostate Luminal Cells to Prostate Progenitors and Cancer. CRPC
19  2018 The feasibility of prostate-specific membrane antigen positron emission tomography(PSMA PET/CT)-guided radiotherapy in oligometastatic prostate cancer patients. CS
20  2018 The inhibitory effect of Cordycepin on the proliferation of cisplatin-resistant A549 lung cancer cells. ---
21  2017 Anti-Androgen Abiraterone Acetate Improves the Therapeutic Efficacy of Statins on Castration-Resistant Prostate Cancer Cells. AR, PCa
22  2017 Exploiting ROS and metabolic differences to kill cisplatin resistant lung cancer. LDHA, ROS
23  2017 Identifying Dysregulated Epigenetic Enzyme Activity in Castrate-Resistant Prostate Cancer Development. HAT, HS, PCa
24  2017 miR-25-3p reverses epithelial-mesenchymal transition via targeting Sema4C in cisplatin-resistance cervical cancer cells. EMT
25  2017 TAZ overexpression is associated with epithelial-mesenchymal transition in cisplatin-resistant gastric cancer cells. EMT
26  2016 Epidermal growth factor induces p38 MAPK-dependent G0/G1-to-S transition in prostate cancer cells upon androgen deprivation conditions. EGF
27  2016 Measurement of serum testosterone during androgenic suppression in patients with prostate cancer: A systematic review. AS, ST
28  2016 Plasma macrophage-stimulating protein and hepatocyte growth factor levels are associated with prostate cancer progression. CRPC, ELISA, HGF, HGFA, MSP, RON
29  2015 Cellular prostatic acid phosphatase (cPAcP) serves as a useful biomarker of histone deacetylase (HDAC) inhibitors in prostate cancer cell growth suppression. ADT, AR, cPAcP, HDAC, PCa
30  2015 ErbB-2 signaling plays a critical role in regulating androgen-sensitive and castration-resistant androgen receptor-positive prostate cancer cells. ADT, AI, AS, PCa
31  2015 The lncRNA DRAIC/PCAT29 Locus Constitutes a Tumor-Suppressive Nexus. AD, ADT, AR, DFS, lncRNA
32  2015 The RNA-binding protein Sam68 regulates expression and transcription function of the androgen receptor splice variant AR-V7. AR, PCa, RBP
33  2014 ERG rearrangement and protein expression in the progression to castration-resistant prostate cancer. AR, HN, TMA
34  2014 In vitro chronic administration of ERbeta selective ligands and prostate cancer cell growth: hypotheses on the selective role of 3beta-adiol in AR-positive RV1 cells. AD, ERbeta, PC
35  2014 Influence of peripheral whole-blood microRNA-7 and microRNA-221 high expression levels on the acquisition of castration-resistant prostate cancer: evidences from in vitro and in vivo studies. CRPC, miRNAs, PC
36  2014 Survival analysis of patients with biochemical relapse after radical prostatectomy treated with androgen deprivation: Castration-resistance influential factors. ADT, BCR, CI, HR, PSA, RFS, SS
37  2014 Targeting GPR30 with G-1: a new therapeutic target for castration-resistant prostate cancer. AS, CRPC, GPR30, PC
38  2014 [Antisense oligodeoxynucleotide therapy for castration-resistant prostate cancer]. PC
39  2013 Development of an ELISA detecting Tumor Protein 53-Induced Nuclear Protein 1 in serum of prostate cancer patients. ELISA, mAbs, PC, TP53INP1
40  2013 Estrogen receptor beta expression and androgen receptor phosphorylation correlate with a poor clinical outcome in hormone-naive prostate cancer and are elevated in castration-resistant disease. AR, ER, HN, PC
41  2013 Hypoxic tumor kinase signaling mediated by STAT5A in development of castration-resistant prostate cancer. AD, ADT, STAT5A
42  2013 Improvement of a predictive model of castration-resistant prostate cancer: functional genetic variants in TGFbeta1 signaling pathway modulation. ADT, PC, PCR
43  2013 STAT5A/B gene locus undergoes amplification during human prostate cancer progression. PCa
44  2012 A novel role for BDNF-TrkB in the regulation of chemotherapy resistance in head and neck squamous cell carcinoma. ---
45  2012 Androgen receptor is up-regulated by a BLT2-linked pathway to contribute to prostate cancer progression. AR, ROS
46  2012 Carbidopa abrogates L-dopa decarboxylase coactivation of the androgen receptor and delays prostate tumor progression. AR, DDC, PSA
47  2012 Castration resistant prostate cancer is associated with increased blood vessel stabilization and elevated levels of VEGF and Ang-2. ADT, Ang-2, HN, MVD, VEGF
48  2012 Initiation of prostate cancer in mice by Tp53R270H: evidence for an alternative molecular progression. EMT, PIN
49  2012 Prediction of response to androgen deprivation therapy and castration resistance in primary metastatic prostate cancer. ADT, EBI, GS, nPSA, PC
50  2012 Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer. AD, ADT, AHS, AUC, HF, PC, qIHC, RT, VD, VF, VS
51  2011 Dual blockade of PKA and NF-kappaB inhibits H2 relaxin-mediated castrate-resistant growth of prostate cancer sublines and induces apoptosis. AR, BPH, NF-kappaB
52  2011 Effects of commercially available soy products on PSA in androgen-deprivation-naive and castration-resistant prostate cancer. ADT, PSA
53  2011 Human prostate cancer xenografts in lit/lit mice exhibit reduced growth and androgen-independent progression. AI, PCa
54  2011 IkappaB-Kinase-epsilon (IKKepsilon/IKKi/IkappaBKepsilon) expression and localization in prostate cancer tissues. HS, IKKepsilon, PCa, PIN
55  2011 Minireview: Alternative activation pathways for the androgen receptor in prostate cancer. AR
56  2009 Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancer. FISH
57  2009 Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. HS, OS, PC, PSA-P, ROD, SWOG
58  2007 Curcumin induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by modulating Akt and p38 MAPK. ---
59  2007 EF24 induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by increasing PTEN expression. ---
60  2006 Reversal to cisplatin sensitivity in recurrent human ovarian cancer cells by NCX-4016, a nitro derivative of aspirin. HOCCs
61  1993 Toxicity of and mutagenesis by chlorate are independent of nitrate reductase activity in Chlamydomonas reinhardtii. CS, NR